Abstract:Objectives. To evaluate the role of radiotherapy (RT) for hepatocellular carcinoma (HCC) patients with abdominal lymph node (LN) metastasis at our institution in the past 7 years.Methods and Materials: We identified 125 patients with HCC metastasis to regional LNs treated with or without external beam RT (EBRT) between 1998 and 2004. Clinical characteristics collected included a-fetoprotein status, gamma-glutamyltransferase, status of intrahepatic tumors (size and number), previous therapy for intrahepatic tumors, metastatic LN status (location, number, and size), tumor thrombi, and Child-Pugh classification. Of the 125 patients, 62 received local limited EBRT and were classified as the EBRT group. They received locoregional LN irradiation. The tumor dose ranged from 40 to 60 Gy in daily 2.0-Gy fractions, 5 times weekly. Another 63 patients, who did not receive EBRT, were selected from hospitalized patients in the same period and were classified as the non-EBRT group. The parameters studied included survival rates and tumor response to EBRT both as demonstrated by clinical symptoms and as seen on CT. The Kaplan-Meier method was used to evaluate the survival rates, and the Cox regression model was used to identify predictors of outcome.Results: After EBRT, partial responses and complete responses were observed in 37.1% and 59.7% of patients, respectively. The median survival was 9.4 months (95% confidence interval 5.8-13.0) for the EBRT group and 3.3 months (95% confidence interval, 2.7-3.9) for the non-EBRT group (p < 0.001). Multivariate analysis showed that multiple intrahepatic primary tumors, occurrence of tumor thrombi, no therapy for intrahepatic tumors, and greater Child-Pugh classification were related to a poorer prognosis in all patients. In the EBRT group, the survival periods decreased as the distance of LN involvement from the liver increased (following the natural flow of lymph) and was also associated with the intrahepatic primary tumor size. The incidence of death resulting from LN-related complications was lower in the EBRT group.Conclusion: Lymph node metastasis from HCC is sensitive to EBRT. EBRT with 25 fractions of 2 Gy is an effective palliative treatment for patients with LN metastases from HCC presenting with good performance status and may prolong overall survival. (c) 2005 Elsevier Inc.

Radiotherapy for Adrenal Gland Metastases from Hepatocellular Carcinoma.

Radiotherapy Treatment of Adrenal Gland Metastases from Hepatocellular Carcinoma: Clinical Features and Prognostic Factors

Radiation Therapy for Adrenal Gland Metastases from Hepatocellular Carcinoma.

Radiation Therapy for Hepatocellular Carcinoma: Current Status and Perspectives from Our Experience

Two-institution results of Stereotactic Body Radiation Therapy (SBRT) for treating adrenal gland metastases from liver cancer

Effect and Safety of Robotic Radiosurgery in the Treatment of 42 Patients with Adrenal Metastases

Advances in radiotherapy and immunity in hepatocellular carcinoma

Radiotherapy Efficacy and Prognostic Factors in Hepatocellular Carcinoma Patients with Cardiophrenic Angle or Superior Diaphragmatic Lymph Nodes Metastasis

Long-term outcome of adjuvant radiotherapy upon postoperative relapse of centrally located hepatocellular carcinoma: a real-world study

Safety and Efficacy of Hypofractionated Radiotherapy Combined with Tyrosine Kinase Inhibitors in Patients with Lung Metastases after Liver Transplantation for Hepatocellular Carcinoma

Radiation Therapy for the Locoregional Lymph Node Metastases from Hepatocellular Carcinoma, Phase I Clinical Trial

Benefit of Radiotherapy for 90 Patients with Resected Intrahepatic Cholangiocarcinoma and Concurrent Lymph Node Metastases

Adjuvant radiotherapy in central hepatocellular carcinoma after narrow-margin hepatectomy: A 10-year real-world evidence

Consideration of Role of Radiotherapy for Lymph Node Metastases in Patients with HCC: Retrospective Analysis for Prognostic Factors from 125 Patients

Radiotherapy is superior to transarterial chemoembolization as adjuvant therapy after narrow-margin hepatectomy in patients with hepatocellular carcinoma: A single-center prospective randomized study

Efficacy of radiotherapy in combined treatment of hepatocellular carcinoma patients with portal vein tumor thrombus: a real-world study

Radiotherapy with Targeted Therapy or Immune Checkpoint Inhibitors for Hepatocellular Carcinoma with Hepatic Vein and/or Inferior Vena Cava Tumor Thrombi

Adjuvant Radiotherapy in Centrally Located Hepatocellular Carcinomas after Hepatectomy with Narrow Margin (<1 Cm): a Prospective Randomized Study.

The research for clinical prognotic factors of metastatic liver cancer treated with radiotherapy

Abstract No. 552 Hepatotoxicity and Survival in Patients with Cirrhotic Hepatocellular Carcinoma versus Liver Metastatic Disease After Yttrium-90 Radioembolization

Adrenal Metastasis of Hepatocellular Carcinoma in Patients following Liver Resection or Liver Transplantation: Experience from a Tertiary Referral Center